Wells Fargo
ANTH

Wells Fargo’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Wells Fargo’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-87
Closed – – 6777
2018
Q1 		$0 Sell
87
-8,500
-99% -$12.7K ﹤0.01% 6731
2017
Q4 		$14K Sell
8,587
-3,500
-29% -$6.02K ﹤0.01% 5862
2017
Q3 		$17K Buy
12,087
+9,375
+346% +$13.3K ﹤0.01% 5758
2017
Q2 		$4K Sell
2,712
-59
-2% -$132 ﹤0.01% 5983
2017
Q1 		$10K Buy
2,771
+1,250
+82% +$5.91K ﹤0.01% 5890
2016
Q4 		$8K Sell
1,521
-75
-5% -$1.3K ﹤0.01% 5873
2016
Q3 		$40K Buy
1,596
+13
+0.8% +$328 ﹤0.01% 5389
2016
Q2 		$39K Sell
1,583
-298
-16% -$8.42K ﹤0.01% 5299
2016
Q1 		$54K Buy
1,881
+469
+33% +$12.7K ﹤0.01% 5200
2015
Q4 		$52K Sell
1,412
-7
-0.5% -$309 ﹤0.01% 5268
2015
Q3 		$69K Buy
1,419
+914
+181% +$63.9K ﹤0.01% 5128
2015
Q2 		$35K Buy
505
+349
+224% +$16.2K ﹤0.01% 5437
2015
Q1 		$6K Hold
156
– – ﹤0.01% 5791
2014
Q4 		$2K Hold
156
– – ﹤0.01% 6045
2014
Q3 		$2K Buy
+156
New +$3.28K ﹤0.01% 6023

Other funds holding ANTH

WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Wells Fargo's ANTH Position: Q2 2018 in Review

Wells Fargo sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 87 shares.

Wells Fargo first reported a position in ANTH in Q3 2014 and held it in 15 quarters. The position peaked at $69K in Q3 2015. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.

  • Wells Fargo reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • Wells Fargo sold 87 Anthera Pharmaceuticals, Inc. shares in Q2 2018.
  • Wells Fargo first reported a position in Anthera Pharmaceuticals, Inc. in Q3 2014 and held it in 15 quarters.
  • Wells Fargo's Anthera Pharmaceuticals, Inc. position peaked at $69K in Q3 2015.
  • 5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.

Based on Wells Fargo's 13F filing for Q2 2018, filed 1 Aug 2018.